Clinical Report: SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Overview

SGLT2 inhibitors are associated with a significantly lower risk of late-onset epilepsy, status epilepticus, and initiation of antiseizure medications in older patients with type 2 diabetes compared to DPP-4 inhibitors. This observational study highlights potential neuroprotective benefits of SGLT2 inhibitors, although causality cannot be established due to the study design.

Background

The management of type 2 diabetes in older adults is critical due to the increased risk of comorbidities, including neurological disorders. Recent studies suggest that SGLT2 inhibitors may offer additional benefits beyond glycemic control, particularly in reducing the incidence of epilepsy. Understanding these associations is essential for optimizing treatment strategies in this vulnerable population.

Data Highlights

Key Findings

• SGLT2 inhibitors were associated with a 45% lower risk of late-onset epilepsy compared to DPP-4 inhibitors.
• Patients on SGLT2 inhibitors had a 62% lower risk of status epilepticus.
• Initiation of antiseizure medications was 37% lower in patients receiving SGLT2 inhibitors.
• Subgroup analyses indicated lower risks across various demographics, particularly in patients aged 80 and older.
• Findings were consistent across sensitivity analyses, despite limitations in the study design, including reliance on coded diagnoses and lack of detailed neurologic information.

Clinical Implications

Healthcare providers should consider the potential neuroprotective effects of SGLT2 inhibitors when treating older adults with type 2 diabetes. While these findings are promising, further research is needed to establish causality and understand the underlying mechanisms.

Conclusion

The association between SGLT2 inhibitors and reduced epilepsy risk presents a compelling area for further investigation. Clinicians should remain informed about emerging evidence as it may influence treatment decisions for older patients with type 2 diabetes, keeping in mind the observational nature of the study.

References

1. Bing-Hua Lin et al., Epilepsia, 2023 -- SGLT2 Inhibitors Linked to Lower Epilepsy Risk
2. The New Gastroenterologist — GLP-1s Increase GERD Risk Over SGLT2 Inhibitors in T2D
3. Frontiers in Endocrinology — SodiuM glucose cotrANsporter-2 (SGLT-2) inhibitors in the treatment of type II DiAbetes in Tuscany: utiLizatiOn patteRns, and relatEd clinical use evaluation; the MANDALORE study protocol
4. Critical Care (Springer) — Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study
5. The New Gastroenterologist — Comparative Gastrointestinal Risk of GLP-1 Receptor Agonists and Tirzepatide
6. American Diabetes Association Releases “Standards of Care in Diabetes—2026”
7. Checking your browser - reCAPTCHA
8. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society - Tracy Glauser, Shlomo Shinnar, David Gloss, Brian Alldredge, Ravindra Arya, Jacquelyn Bainbridge, Mary Bare, Thomas Bleck, W. Edwin Dodson, Lisa Garrity, Andy Jagoda, Daniel Lowenstein, John Pellock, James Riviello, Edward Sloan, David M. Treiman, 2016